

Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022

<https://marketpublishers.com/r/PF102314F7DEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PF102314F7DEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Polo-Like Kinase 1 (PLK1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Polo-Like Kinase 1 (PLK1) Inhibitor Understanding

Polo-Like Kinase 1 (PLK1) Inhibitor: Overview

Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. PLK1 is one of the five members of the PLK family and are found in the nuclei of all dividing cells. PLKs are defined by two conserved features: an N terminal Ser/Thr kinase domain and a C-terminal duplicated Polo-box region. PLK1 is the most extensively studied of five members of the polo-like family and is primarily known for operating as a pleiotropic master regulator of the cell cycle from entry into mitosis to the initiation of cytokinesis. This includes regulating the activity of proteins involved in establishing centromeres, initiating spindle checkpoint signaling and

coordinating the activity of the spindle checkpoint. PLK1 inhibition has been shown to cause mitotic block and apoptosis of tumor cells. The potential of PLK1 inhibitors as cancer therapeutic has been widely explored, which resulted in several PLK1 inhibitors in clinical trials following their preclinical successes.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Polo-Like Kinase 1 (PLK1) Inhibitor R&D. The therapies under development are focused on novel approaches for Polo-Like Kinase 1 (PLK1) Inhibitor.

Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs Chapters

This segment of the Polo-Like Kinase 1 (PLK1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polo-Like Kinase 1 (PLK1) Inhibitor Emerging Drugs

Onvansertib: Cardiff Oncology

Onvansertib is a first-in-class, third-generation, oral and highly-selective PLK1 inhibitor. Onvansertib selectively inhibits PLK1, a proven therapeutic target that is over-expressed in most cancers. Onvansertib works synergistically in combination with chemotherapies and targeted therapeutics. In May 2020, FDA has granted Fast Track designation to onvansertib (PCM-075) for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).

CYC-140: Cyclacel Pharmaceuticals

CYC140 is a novel, small molecule, selective, ATP-competitive, Plk1 inhibitor. CYC140 shows selective target inhibition, impressive efficacy and cures human tumor xenografts at non-toxic doses. The molecule is in clinical evaluation for the treatment of acute

myeloid leukemia and myelodysplastic syndrome.

Further product details are provided in the report.....

Polo-Like Kinase 1 (PLK1) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Polo-Like Kinase 1 (PLK1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Polo-Like Kinase 1 (PLK1) Inhibitor

There are approx. 8+ key companies which are developing the Polo-Like Kinase 1 (PLK1) Inhibitor. The companies which have their Polo-Like Kinase 1 (PLK1) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Cardiff Oncology.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Polo-Like Kinase 1 (PLK1) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polo-Like Kinase 1 (PLK1) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Polo-Like Kinase 1 (PLK1) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polo-Like Kinase 1 (PLK1) Inhibitor drugs.

Polo-Like Kinase 1 (PLK1) Inhibitor Report Insights

Polo-Like Kinase 1 (PLK1) Inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Polo-Like Kinase 1 (PLK1) Inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Polo-Like Kinase 1 (PLK1) Inhibitor drugs?

How many Polo-Like Kinase 1 (PLK1) Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Polo-Like Kinase 1 (PLK1) Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polo-Like Kinase 1 (PLK1) Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Polo-Like Kinase 1 (PLK1) Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Oncoheroes Biosciences

Cyclacel Pharmaceuticals

Cardiff Oncology

Onconova Therapeutics

Sentinel oncology

Key Products

Volasertib

CYC-140

Onvansertib

Rigosertib

SOL686

Contents

Introduction

Executive Summary

Polo-Like Kinase 1 (PLK1) Inhibitor: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Polo-Like Kinase 1 (PLK1) Inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Polo-Like Kinase 1 (PLK1) Inhibitor companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Polo-Like Kinase 1 (PLK1) Inhibitor Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Onvansertib: Cardiff Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CYC-140: Cyclacel Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Volasertib: Oncoheroes Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies**Polo-Like Kinase 1 (PLK1) Inhibitor Key Products****Polo-Like Kinase 1 (PLK1) Inhibitor- Unmet Needs****Polo-Like Kinase 1 (PLK1) Inhibitor- Market Drivers and Barriers****Polo-Like Kinase 1 (PLK1) Inhibitor- Future Perspectives and Conclusion****Polo-Like Kinase 1 (PLK1) Inhibitor Analyst Views****Polo-Like Kinase 1 (PLK1) Inhibitor Key Companies****Appendix**

List Of Tables

LIST OF TABLES

Table 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Polo-Like Kinase 1 (PLK1) Inhibitor

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PF102314F7DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PF102314F7DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970